Literature DB >> 3392243

Alprazolam pharmacokinetics in women on low-dose oral contraceptives.

J M Scavone1, D J Greenblatt, A Locniskar, R I Shader.   

Abstract

Sixteen women chronically using low-dose estrogen-containing oral contraceptive steroids (OCs) and 23 drug-free control women received a single 1-mg oral dose of alprazolam. Multiple plasma samples drawn during 48 hours after the dose were analyzed by electron-capture gas-liquid chromatography. There were no significant differences between controls and oral contraceptive users in alprazolam volume of distribution (1.27 versus 1.39 L/kg), elimination half-life (11.9 versus 12.3 hours), total clearance (1.36 versus 1.39 mL/min/kg), or total area under the plasma concentration versus time curve (227 versus 243 ng/mL X hr). Alprazolam free fraction in plasma was slightly but significantly greater in the oral contraceptive group as opposed to the control group (28.4 versus 27.0% unbound), respectively. However, comparison of free clearance between groups revealed no significant difference (4.61 versus 4.89 mL/min/kg, respectively). Thus, low-dose estrogen-containing oral contraceptives do not significantly influence the metabolic clearance of alprazolam.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392243     DOI: 10.1002/j.1552-4604.1988.tb05759.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.

Authors:  S Palovaara; K T Kivistö; P Tapanainen; P Manninen; P J Neuvonen; K Laine
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 2.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.

Authors:  Sanna Palovaara; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

4.  Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms.

Authors:  Marija Tubic-Grozdanis; John M Hilfinger; Gordon L Amidon; Jae Seung Kim; Paul Kijek; Petra Staubach; Peter Langguth
Journal:  Pharm Res       Date:  2008-01-24       Impact factor: 4.200

Review 5.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.